Mei ST, Li L, Li JJ. Aloe-derived micellar emulsion dressing combination therapy for pressure ulcers: A case report and review of literature. World J Clin Cases 2026; 14(3): 113275 [DOI: 10.12998/wjcc.v14.i3.113275]
Corresponding Author of This Article
Jie-Jing Li, PhD, Associate Professor, Department of Research, Guangzhou Oriplamacy Technology Co., Ltd., No. 918 Middle Guangzhou Avenue, Guangzhou 510000, Guangdong Province, China. jiejingli@ext.jnu.edu.cn
Research Domain of This Article
Nursing
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Jan 26, 2026 (publication date) through Jan 23, 2026
Times Cited of This Article
Times Cited (0)
Journal Information of This Article
Publication Name
World Journal of Clinical Cases
ISSN
2307-8960
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Mei ST, Li L, Li JJ. Aloe-derived micellar emulsion dressing combination therapy for pressure ulcers: A case report and review of literature. World J Clin Cases 2026; 14(3): 113275 [DOI: 10.12998/wjcc.v14.i3.113275]
World J Clin Cases. Jan 26, 2026; 14(3): 113275 Published online Jan 26, 2026. doi: 10.12998/wjcc.v14.i3.113275
Aloe-derived micellar emulsion dressing combination therapy for pressure ulcers: A case report and review of literature
Shu-Ting Mei, Lu Li, Jie-Jing Li
Shu-Ting Mei, Department of Clinical, Guangzhou Dongyuan Tianlong Traditional Chinese Medicine Clinic, Guangzhou 510000, Guangdong Province, China
Lu Li, Department of Testing, Guangzhou Ultimate Molecule Technology Co., Ltd., Guangzhou 510000, Guangdong Province, China
Jie-Jing Li, Department of Research, Guangzhou Oriplamacy Technology Co., Ltd., Guangzhou 510000, Guangdong Province, China
Jie-Jing Li, Guangzhou-Hong Kong-Macao Overseas Chinese Diabetes Innovation Institute, First Affiliated Hospital of Jinan University, Guangzhou 510630, Guangdong Province, China
Co-first authors: Shu-Ting Mei and Lu Li.
Author contributions: Mei ST and Li L contributed equally to this work and are co-first authors. Mei ST and Li L contributed to writing - original draft; Mei ST was responsible for data collection; Li L contributed to data curation, formal analysis, and writing - review and editing; Li JJ provided supervision, project administration, and resources; all authors have read and approved the final manuscript.
Informed consent statement: Written informed consent was obtained from the patient’s legal guardian for publication of this case report and any accompanying images.
Conflict-of-interest statement: Author Li JJ is an employee and Chief Scientist of Guangzhou Oriplamacy Technology Co., Ltd., the manufacturer of the product (AVBER). Mei ST and Li L have no conflicts of interest to disclose. The publication of this article, including the Article Processing Charge, was funded by Guangzhou Oriplamacy Technology Co., Ltd. The funder had no role in the study design, data collection, analysis, or interpretation of the results.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jie-Jing Li, PhD, Associate Professor, Department of Research, Guangzhou Oriplamacy Technology Co., Ltd., No. 918 Middle Guangzhou Avenue, Guangzhou 510000, Guangdong Province, China. jiejingli@ext.jnu.edu.cn
Received: August 21, 2025 Revised: September 30, 2025 Accepted: January 9, 2026 Published online: January 26, 2026 Processing time: 155 Days and 0.1 Hours
Abstract
BACKGROUND
The management of stage IV pressure ulcers (PUs) in elderly, high-risk surgical patients remains a formidable clinical challenge, often limited by the invasiveness and risks of standard surgical options. Although Aloe vera has known wound-healing properties, clinical evidence of its efficacy in complex, severe PUs is scarce. This case report details a novel, non-invasive combination therapy centered around an aloe-derived micellar emulsion dressing (Aloe vera barbadensis extract R, AVBER) and demonstrates its potential as a viable palliative strategy for this vulnerable population.
CASE SUMMARY
A 90-year-old, severely malnourished female (body mass index 13.3 kg/m2) presented with extensive, bilateral stage IV ischial PUs following a femoral fracture. Given her frailty and high surgical risk, a conservative regimen was initiated. This regimen comprised the topical application of an AVBER dressing, targeted red light therapy, and intensive nutritional support, all guided through telemedicine. Over a period of 8.5 months, this treatment was associated with complete healing of the left ulcer and near-complete resolution (from 15 cm × 15 cm to 0.8 cm × 3.0 cm) of the right ulcer, with no serious adverse events reported. The PU scale for healing score for the right ischial ulcer decreased markedly from 17 to 6.
CONCLUSION
AVBER-based combination therapy represents a promising non-invasive option for managing severe PUs in surgically ineligible patients.
Core Tip: This case report describes the successful management of severe (stage IV) pressure ulcers in a high-risk, non-surgical 90-year-old patient using a novel aloe-derived micellar emulsion dressing combined with red light therapy and nutritional support. The aloe-derived micellar emulsion dressing, containing the bioactive component acemannan, was associated with significant wound healing, including complete closure of one ulcer and a marked reduction in another. This multimodal, non-invasive approach is a promising and cost-effective palliative strategy for managing complex wounds in frail, elderly patients for whom surgical options are contraindicated.
